Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction

PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 days decreased the number of inflammatory cells and attenuated left ventricular dilation. Cardiac function and remodeling...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Muhammad, Pulli, Benjamin, Courties, Gabriel, Tricot, Benoit, Sebas, Matthew, Iwamoto, Yoshiko, Hilgendorf, Ingo, Schob, Stefan, Dong, Anping, Zheng, Wei, Skoura, Athanasia, Kalgukar, Amit, Cortes, Christian, Ruggeri, Roger, Swirski, Filip K., Nahrendorf, Matthias, Buckbinder, Leonard, Chen, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113523/
https://www.ncbi.nlm.nih.gov/pubmed/30167547
http://dx.doi.org/10.1016/j.jacbts.2016.09.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113523/
https://www.ncbi.nlm.nih.gov/pubmed/30167547
http://dx.doi.org/10.1016/j.jacbts.2016.09.004

Ejemplares similares